文献速递血液净化与透析

DOPPS研究:不同地区血液透析患者心血管事件发生率

Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions-A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS).
PubMed 文献 · Kidney Int Rep · 2019-03-28

基于DOPPS第4、5期前瞻性队列,纳入16560例血液透析患者,量化全因死亡、MACE及MACE+(含心衰和血栓栓塞)事件率。MACE+发生率北美最高(19.4/100患者年),欧洲17.4,日本最低7.5;高危患者事件率升高36%~72%,且贫血指南变化未见影响事件率。

要点

  • 血液透析患者MACE+发生率地区差异明显,北美最高、日本最低。
  • 心血管高危患者MACE+事件率较总体升高36%~72%。
  • 贫血指南变化前后(DOPPS第4、5期)事件结局差异极小。

核心结论

  • 血液透析患者心血管事件率高且存在地区差异,高危和ESA低反应患者事件率显著更高。
  • 近期贫血管理指南变化未见影响心血管事件率。

研究设计与样本

  • 前瞻性队列研究,纳入DOPPS第4期(2009-2011)和第5期(2012-2015)共16560例血液透析患者。
  • 其中包含8660例心血管高危患者和884例ESA低反应患者。

主要发现

  • MACE+发生率(每100患者年):北美19.4(95%CI 18.2-20.7),欧洲17.4(95%CI 16.6-18.1),日本7.5(95%CI 6.9-8.1)。
  • 高危人群中MACE+事件率升高:北美36%,欧洲45%,日本72%。
  • 死亡占MACE+事件的74%以上。
  • ESA低反应患者与心血管高危患者的MACE+事件率在北美和欧洲队列中相似。
  • DOPPS第4期与第5期之间的结局差异极小。

临床怎么用

  • 应关注血液透析患者尤其是心血管高危和ESA低反应患者的心血管事件风险。
  • 地区间事件率差异可为未来贫血相关心血管结局研究的设计提供参照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cardiovascular (CV) morbidity and mortality are excessively high among hemodialysis (HD) patients. Anemia is a common complication of chronic kidney disease (CKD) and a known risk factor for CV events. To understand the impact of the recent regulatory and guideline changes in anemia management, we examined regional CV event rates in high-risk and erythropoiesis-stimulating agent (ESA)-hyporesponsive HD patients. METHODS: A prospective cohort study including 16,560 HD patients, 8660 CV high-risk, and 884 hyporesponsive to ESAs, from the Dialysis Outcomes and Practice Patterns Study (DOPPS) phase 4 (2009-2011) and phase 5 (2012-2015) was conducted to quantify all-cause mortality, major adverse cardiovascular events (MACE), and MACE plus heart failure and thromboembolic events (MACE+). RESULTS: The MACE+ rates (per 100 patient-years) were highest in North America (NA) (19.4; 95% CI = 18.2-20.7), followed by Europe (EU) (17.4; 95% CI = 16.6-18.1) and lowest in Japan (7.5; 95% CI = 6.9-8.1). When restricted to the high CV risk population, rates increased by 36% in NA, 45% in EU, and 72% in Japan. Mortality accounted for >74% of MACE+ events. MACE+ rates in ESA-hyporesponsive patients and high CV risk patients were similar in NA and EU cohorts. There were minimal differences in outcomes between the DOPPS phases 4 and 5. CONCLUSION: Cardiovascular event rates are high in the HD population, vary by geographic region, and are substantially higher in high CV risk patients and ESA-hyporesponsive patients; however, the rates appear not to be affected by anemia guideline changes. The findings from this study will be essential to contextualize the design of future CV anemia-related outcome studies and clinical trials.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Stirnadel-Farrant HA, Karaboyas A, Cizman B, et al. Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions-A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int Rep. 2019. PMID: 31194073. doi:10.1016/j.ekir.2019.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。